The Clinical Research On The Treatment Of Ovarian Tumour By Lichongshengsuiyin Combined With Chemotherapy

Objective:access lichongshengsuiyin Combined TC in the treatment of ovarian cancer after chemotherapy in patients with short-term clinical efficacy and attenuated chemotherapy medicine synergies.Methods:50 ovarian cancer patients needed chemotherapy were randomly divided into treatment group (TCM+chemotherapy) and control group (chemotherapy alone), each 25. Chinese medicine symptom effect scoring, physical score, quality of life score, and the toxicity and tumor markers CA125 to assess changes in values of Lichongshengsuiyin combine TC in the treatment of ovarian cancer patients after therapy.Results:1. In improving the symptoms of TCM in the treatment group the total effective rate (84.00%) was significantly higher, compared with the control group (48.00%). there were significant differences (P<0.01). It shows treatment group patients in the TCM treatment syndromes exceed the control group patients (P<0.05).2. Karnofsky score of the treatment group before the treatment compared with after the treatment is no significant difference (P>0.05). Karnofsky score of the control group before the treatment compared with after the treatment is no significant difference (P>0.05). After treatment, Karnofsky score statistical comparison, there are significant differences (P<0.05), shows the treatment group exceed the control group in physical condition.3. QOL points of the treatment group before the treatment compared with after the treatment is no significant difference (P>0.05). QOL points of the control group before the treatment compared with after the treatment is significant difference (P>0.05). Statistical comparison between the two group after treatment, there were significant differences (p<0.01), showed that the treatment group can significantly improve the quality of life of the chemotherapy patients.4. Toxicity and safety indicators show:WBC, platelet count, nausea, vomiting, hair loss, blood urea nitrogen values of the treatment group compared with the control group is significant difference (P<0.01). Granulocyte of the treatment group compared with the control group is statistically significant difference (P<0.05), and the intervention rate of the treatment group compared with the control group is significant difference (P<0.01), showed that the treatment group can reduce chemotherapy-induced bone marrow suppression, gastrointestinal reactions, renal damage and other side reaction.5. The changes in tumor markers-CA125 of the treatment group before the treatment compared with after the treatment is significant difference (P <0.005). The changes in tumor markers-CA125 of the control group before the treatment compared with after the treatment is statistically significant difference (P<0.05). the statistical comparison between the two treatment group after the treatment is significantly different (P<0.05), showed that the treatment group and control group can effectively reduce the value of CA125, but the decrease speed and range of CA125 in treatment group even more apparent.Conclusion:1. LiChongShengSuiYin can improve the life quality of ovariancancer patients with postoperative chemotherapy.2. LiChongShengSuiYin can prevent and reduce chemotherapy-induced bone marrow suppression, gastrointestinal reactions, renal damage and other side effects.3. LiChongShengSuiYin can increase the role of chemotherapy drugs kill cancer cells.